Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
117 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Renal Anemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Renal Anemia - Pipeline Review, H2 2014', provides an overview of the Renal Anemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Renal Anemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Renal Anemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Renal Anemia Overview 9 Therapeutics Development 10 Pipeline Products for Renal Anemia - Overview 10 Pipeline Products for Renal Anemia - Comparative Analysis 11 Renal Anemia - Therapeutics under Development by Companies 12 Renal Anemia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Renal Anemia - Products under Development by Companies 19 Renal Anemia - Companies Involved in Therapeutics Development 21 Hospira, Inc. 21 Medgenics Inc. 22 Amgen Inc. 23 GlaxoSmithKline plc 24 Daiichi Sankyo Company, Limited 25 FibroGen, Inc. 26 Japan Tobacco Inc. 27 Zydus Cadila Healthcare Limited 28 Bayer AG 29 3SBio Inc. 30 ProMetic Life Sciences Inc. 31 JCR Pharmaceuticals Co., Ltd. 32 CCM Duopharma Biotech Bhd. 33 Panacea Biotec Limited 34 Affymax, Inc. 35 Myungmoon pharmaceutical Co.,Ltd. 36 Intas Pharmaceuticals Ltd. 37 Acceleron Pharma, Inc. 38 Pieris AG 39 Noxxon Pharma AG 40 Aprogen, Inc. 41 Dong-A Socio Group 42 Renal Anemia - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 peginesatide - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 darbepoetin alfa - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 epoetin - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 epoetin alfa - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Peg-EPO - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 roxadustat - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 sotatercept - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 GSK-1278863 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 lexaptepid pegol - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 molidustat - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 MDGN-201 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 PEG-EPO - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 FG-2216 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PRS-080 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 epoetin alfa - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 JTZ-951 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 epoetin alfa - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 DS-1093 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 NuPIAO - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 PBI-1402 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 PBI-4050 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 ZP-EPO - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 darbepoetin alfa - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 darbepoetin alfa - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 darbepoetin alfa - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 darbepoetin alfa - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 MM-P01-01 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Recombinant Protein for Renal Anemia - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Renal Anemia - Recent Pipeline Updates 91 Renal Anemia - Dormant Projects 106 Renal Anemia - Discontinued Products 107 Renal Anemia - Product Development Milestones 108 Featured News & Press Releases 108 Sep 26, 2013: ProMetic's Lead Drug Candidate, PBI-4050, Enters Clinical Program 108 Sep 13, 2013: Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP for Pediatric Patients with renal anemia in Japan 108 Jul 31, 2013: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease 109 Apr 16, 2013: Amgen To Pay US $24.9m To Resolve False Claims Act Allegations 109 Jan 16, 2013: Amgen Announces Top-Line Results Of Phase III Aranesp RED-HF Trial 110 Dec 12, 2012: FibroGen And Astellas Pharma Initiates Phase III Trial Of FG-4592/ASP1517 For Treatment Of Anemia Of Chronic Kidney Disease 111 Nov 05, 2012: FibroGen Reports Data From Phase II Study Of FG-4592 Hemoglobin Correction And Maintenance In End-Stage Renal Patients 112 Oct 31, 2012: FibroGen To Present Phase II Data Of FG-4592 At American Society Of Nephrology Kidney Week 2012 113 Oct 25, 2012: Sandoz Begins Phase III Studies In US For Biosimilar Epoetin Alfa 114 Feb 13, 2012: Xenetic Commences Phase I/IIa IV Trial For ErepoXen 114 Appendix 116 Methodology 116 Coverage 116 Secondary Research 116 Primary Research 116 Expert Panel Validation 116 Contact Us 117 Disclaimer 117
List of Tables Number of Products under Development for Renal Anemia, H2 2014 10 Number of Products under Development for Renal Anemia - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Development by Companies, H2 2014 (Contd..1) 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Comparative Analysis by Unknown Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Development by Companies, H2 2014 (Contd..1) 20 Renal Anemia - Pipeline by Hospira, Inc., H2 2014 21 Renal Anemia - Pipeline by Medgenics Inc., H2 2014 22 Renal Anemia - Pipeline by Amgen Inc., H2 2014 23 Renal Anemia - Pipeline by GlaxoSmithKline plc, H2 2014 24 Renal Anemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 25 Renal Anemia - Pipeline by FibroGen, Inc., H2 2014 26 Renal Anemia - Pipeline by Japan Tobacco Inc., H2 2014 27 Renal Anemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 28 Renal Anemia - Pipeline by Bayer AG, H2 2014 29 Renal Anemia - Pipeline by 3SBio Inc., H2 2014 30 Renal Anemia - Pipeline by ProMetic Life Sciences Inc., H2 2014 31 Renal Anemia - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2014 32 Renal Anemia - Pipeline by CCM Duopharma Biotech Bhd., H2 2014 33 Renal Anemia - Pipeline by Panacea Biotec Limited, H2 2014 34 Renal Anemia - Pipeline by Affymax, Inc., H2 2014 35 Renal Anemia - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H2 2014 36 Renal Anemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 37 Renal Anemia - Pipeline by Acceleron Pharma, Inc., H2 2014 38 Renal Anemia - Pipeline by Pieris AG, H2 2014 39 Renal Anemia - Pipeline by Noxxon Pharma AG, H2 2014 40 Renal Anemia - Pipeline by Aprogen, Inc., H2 2014 41 Renal Anemia - Pipeline by Dong-A Socio Group, H2 2014 42 Assessment by Monotherapy Products, H2 2014 43 Number of Products by Stage and Target, H2 2014 45 Number of Products by Stage and Mechanism of Action, H2 2014 47 Number of Products by Stage and Route of Administration, H2 2014 49 Number of Products by Stage and Molecule Type, H2 2014 51 Renal Anemia Therapeutics - Recent Pipeline Updates, H2 2014 91 Renal Anemia - Dormant Projects, H2 2014 106 Renal Anemia - Discontinued Products, H2 2014 107
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
